$438.03 Million Growth Expected in Krabbe Disease Treatment Market | North America will become a key market

NEW YORK, April 28, 2022 /PRNewswire/ — “Krabbe Disease Treatment Market by Therapy and Geography – Forecast and Analysis 2022-2026report has been added to Technavio’s offering. With ISO 9001:2015 certification, Technavio has proudly partnered with over 100 Fortune 500 companies for over 16 years.

Technavio has announced its latest market research report titled Krabbe Disease Treatment Market by Therapy and Geography – Forecast and Analysis 2022-2026

The difference in potential growth for the Krabbe Disease Treatment Market between 2021 and 2026 is $438.03 million. For more highlights on market size, CAGR, YOY growth rates, and other important statistics, Download sample report.

Key Market Dynamics:

  • market engine

  • Market challenges

The market is dictated by the special designation of drugs. Additionally, factors such as unmet clinical needs and the practice of consanguineous marriage will have an accelerating effect on the growth of the market. However, the limited number of patients for clinical trials will challenge the growth of the market.

Learn about the major drivers, trends, and challenges impacting market growth. Read our sample report now

The Krabbe Disease Treatment Market report is segmented by Therapy (Anticonvulsants, Muscle Relaxants, HSCT and Others) and Geography (North America, Europe, Asiaand Rest of the World (ROW)).

The anticonvulsants segment will have the largest market share. The segment is driven by the increased use of anticonvulsants in the treatment of seizures or seizures, which is one of the primary symptoms of Krabbe disease in infants. Market growth in the segment will be significant over the forecast period.

North America will be the leading region with 37% of the market growth during the forecast period. The high incidence of Krabbe disease is driving the growth of the regional market.

See our sample report for highlights on other segments’ growth contribution and regional opportunities in the market.

Some companies mentioned with their offers

  • AbbVie Inc.: The company offers Tridone as anticonvulsant drugs for the treatment of Krabbe disease.

  • Acorda Therapeutics Inc.: The company offers baclofen, carisoprodol and chlorzoxazone5 as muscle relaxant drugs for the treatment of Krabbe disease.

  • GlaxoSmithKline Plc: The company offers Lamictal and Voltarenfor tablets as muscle relaxants for the treatment of Krabbe disease.

  • Johnson and Johnson: The company offers Flexeril as a muscle relaxant for the treatment of Krabbe disease.

  • Novartis AG: The company offers Afinitor as an anticonvulsant drug for the treatment of Krabbe disease.

Access more supplier profiles with their key offerings available with Technavio. Download our sample report here

Krabbe Disease Treatment Market 2022-2026: Vendor Analysis

We provide a detailed analysis of approximately 25 providers operating in the treatment of Krabbe disease. Drawing on competitive insights and benchmarking, our Krabbe Disease Treatment Market research report is designed to provide entry support, customer profile and mergers and acquisitions as well as support to the go-to-market strategy.

Krabbe Disease Treatment Market 2022-2026: Key Highlights

  • Market CAGR over the forecast period 2022-2026

  • Detailed information on the factors that will contribute to the growth of the Krabbe disease treatment market over the next five years

  • Estimation of the Krabbe Disease Treatment market size and its contribution to the parent market

  • Predictions on upcoming trends and changes in consumer behavior

  • The growth of the Krabbe disease treatment market

  • Market Competitive Landscape Analysis and Detailed Vendor Information

  • Comprehensive details of the factors that will challenge the growth of the Krabbe Disease Treatment Market vendors

Related reports:

Rheumatoid Arthritis Drugs Market by Type and Geography – Forecast and Analysis 2022-2026

Autoimmune Hemolytic Anemia Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026

Krabbe Disease Treatment Market Scope

Report cover


Page number


base year


Forecast period


Growth momentum and CAGR

Accelerate at a CAGR of 7.56%

Market Growth 2022-2026

$438.03 million

Market structure


Annual growth (%)


Regional analysis

North America, Europe, Asia and Rest of the World (ROW)

Successful market contribution

North America at 37%

Main consumer countries

United States, Canada, United Kingdom, Germany, Japan and China

Competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

AbbVie Inc., Acorda Therapeutics Inc., CENTOGENE NV, GlaxoSmithKline Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Polaryx, Teva Pharmaceutical Industries Ltd. and UCB SA

Market dynamics

Parent Market Analysis, Market Growth Drivers and Barriers, Fast and Slow Growing Segment Analysis, COVID 19 Impact and Future Consumer Dynamics, Market Condition Analysis for the Forecast Period.

Personalization area

If our report does not include the data you are looking for, you can contact our analysts and customize the segments.


1. Summary

2 Market landscape

3 Market sizing

4 Five forces analysis

5 Market Segmentation by Therapy

6 Customer Landscape

7 Geographic landscape

8 drivers, challenges and trends

9 Supplier landscape

10 Vendor Analysis

11 Appendix

About Us
Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With more than 500 industry analysts, Technavio’s library of reports Their customer base consists of companies of all sizes, including more than 100 Fortune 500 companies. Technavio’s exploitable market to identify opportunities in existing and potential markets and assess their competitive positions in changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)



View original content to download multimedia: https://www.prnewswire.com/news-releases/usd-438-03-mn-growth-expected-in-krabbe-disease-treatment-market–north-america- to-emerge-as-a-key-market–technavio-301534466.html


Source link

About Chris Y. Camp

Check Also

Manure processing company LWR finds value in waste

Breadcrumb Links Local company Commercial real estate Karen Schuett, CEO of Calgary’s Livestock Water Recycling, …